MMP-Sensitive Macrophage-Targeted Coenzyme Q10 Nanomedicine for Rheumatoid Arthritis Treatment
Molecular Pharmaceutics · 2025
DOI: 10.1021/acs.molpharmaceut.5c00742 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2025. Verfasst von Aasma Akram und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, Irma Lerma Rangel College of Pharmacy, Texas A&M University, College Station, Texas 77843, United States. Hauptthemen laut MEDLINE: Ubiquinone, Arthritis, Rheumatoid, Macrophages, Matrix Metalloproteinases. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Texas A and M University, Congressionally Directed Medical Research Programs.
Abstract (Originalsprache)
In this work, a novel nanoparticle (NP)-based formulation (i.e., nanomedicine) was developed to specifically deliver coenzyme Q10 (CoQ10) to macrophages for treating rheumatoid arthritis (RA). The NPs containing the matrix metalloproteinase (MMP)-responsive polymer, polyethylene glycol-peptide-phosphatidylethanolamine (PEG-pp-PE), and phosphatidylserine were designed, in which the NPs' PEG "corona" decreased nonspecific interaction, and the overexpressed MMP-2/9 in the inflamed synovium triggered PEG deshielding and PS-mediated phagocytosis. The NPs were prepared by a thin-film hydration method, and their particle size, zeta potential, drug loading, and drug release were determined. CoQ10 could be loaded into the NPs with a drug loading of about 9.7% at the polymer/PS ratio of 50:50. The CoQ10-loaded NPs had a particle size of 13-fold higher than that in fibroblasts (NIH3T3 cells) in the presence of MMPs, whereas this difference was ∼2-fold in the absence of MMPs, indicating the NPs' MMP-sensitive macrophage selectivity. In the LPS- and IFN-γ-stimulated macrophages or cell cocultures, the CoQ10-loaded NPs significantly inhibited the production of pro-inflammatory cytokines (TNF-α, IL-6, and IL-1β), while enhancing the production of the anti-inflammatory cytokine (IL-10) in response to MMP pretreatment. The CoQ10-loaded NPs also significantly inhibited macrophage activation, as evidenced by changes in cell morphology and alterations in macrophage activation-related markers, including CD80, CD86, MHCII, and CD206. The CoQ10-loaded NPs did not show significant cytotoxicity in the tested cells. Our results suggest that the developed MMP-sensitive macrophage-targeted NPs might work as a "smart" nanomedicine for RA treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, Irma Lerma Rangel College of Pharmacy, Texas A&M University, College Station, Texas 77843, United States.
- Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, Government College University Faisalabad, Faisalabad 38000, Pakistan.
ORCID-Profile: Nishat Ara, Muhammad Irfan, Lin Zhu
Förderung
- Texas A and M University
- Congressionally Directed Medical Research Programs
Zitieren
APA
Akram, A., Ara, N., Bhattarai, P., Irfan, M., & Zhu, L. (2025). MMP-Sensitive Macrophage-Targeted Coenzyme Q10 Nanomedicine for Rheumatoid Arthritis Treatment. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c00742
Vancouver
Akram A, Ara N, Bhattarai P, Irfan M, Zhu L. MMP-Sensitive Macrophage-Targeted Coenzyme Q10 Nanomedicine for Rheumatoid Arthritis Treatment. Molecular Pharmaceutics. 2025. doi:10.1021/acs.molpharmaceut.5c00742
BibTeX
@article{Akram2025,
author = {Akram, Aasma and Ara, Nishat and Bhattarai, Prapanna and Irfan, Muhammad and Zhu, Lin},
title = {MMP-Sensitive Macrophage-Targeted Coenzyme Q10 Nanomedicine for Rheumatoid Arthritis Treatment},
journal = {Molecular Pharmaceutics},
year = {2025},
doi = {10.1021/acs.molpharmaceut.5c00742}
}
EUVIMED